Vildagliptin
China [CN] vildagliptin is another orally administered dipeptidyl peptidase-IV (DPP-IV) inhibitor following sitagliptin. It was approved for marketing in the European Union in 2008 by Novartis Pharmaceuticals GMBH of Switzerland and is used for the treatment of type 2 diabetes. Diabetes is a chronic metabolic disease, with its prevalence increasing year by year. Type 2 diabetes is a complex disease caused by the combined effects of multiple genetic and environmental factors. Dipeptidyl peptidase IV(DPP-IV)Chemicalbook inhibitors are a new type of anti-diabetic drugs that exert hypoglycemic effects through multiple mechanisms such as inducing and promoting the biosynthesis and secretion of insulin, inhibiting β -cell apoptosis, inhibiting the secretion of glucagon, and reducing food intake. Moreover, while controlling blood sugar, it can reverse the continuous deterioration of pancreatic islet function in diabetic patients, showing a good application prospect. Vigagliptin is a representative drug of dipeptidyl peptidase inhibitors. In clinical studies, whether used alone or in combination with metformin and insulin, it has shown good anti-diabetic effects and tolerance.
Click enlarge Image